This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, L. Articles by Fukuchi, K.-i. Search for Related Content PubMed PubMed Citation Articles by Li, L. Articles by Fukuchi, K.-i.

(American Journal of Pathology. 2003;163:2155-2164.)
© 2003 American Society for Investigative Pathology

Short Communication

Association of Aortic Atherosclerosis with Cerebral ß-Amyloidosis and Learning Deficits in a Mouse Model of Alzheimer’s Disease

Ling Li^*, Dongfeng Cao^*, David W. Garber^*, Helen Kim and Ken-ichiro Fukuchi

From the Departments of Medicine,^* Pharmacology, and Genetics, University of Alabama at Birmingham, Birmingham, Alabama

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
High fat/high cholesterol diets exacerbate ß-amyloidosis in mouse models of Alzheimer’s disease (AD). It has been impossible, however, to study the relationship between atherosclerosis and ß-amyloidosis in those models because such mice were on atherosclerosis-resistant genetic backgrounds. Here we report the establishment of AD model mice, B6Tg2576, that are prone to atherosclerosis. B6Tg2576 mice were produced by back-crossing Tg2576 mice, an AD mouse model overexpressing human amyloid ß-protein precursor with the Swedish double mutation, to C57BL/6 mice, a strain susceptible to diet-induced atherosclerosis. An atherogenic diet induced aortic atherosclerosis and exacerbated cerebral ß-amyloidosis in B6Tg2576 mice. Compared with age-matched non-transgenic littermates, B6Tg2576 mice developed significantly more diet-induced aortic atherosclerosis. Unexpectedly, normal diet-fed B6Tg2576 mice also developed fatty streak lesions (early atherosclerosis) in the aorta. The aortic atherosclerotic lesion area positively correlated with cerebral ß-amyloid deposits in B6Tg2576 mice on both atherogenic and normal diets. Furthermore, behavioral assessments demonstrated that B6Tg2576 mice fed an atherogenic diet had more spatial learning impairment than those fed a normal diet. Our results suggest that synergistic mechanisms may be involved in the pathogenesis of atherosclerosis and AD. These findings may have important implications in the prevention and treatment of cardiovascular diseases as well as AD.

Mice do not develop atherosclerosis and ß-amyloidosis even in old age without genetic and/or dietary manipulations.^13,14 Indeed, Tg2576 mice, an AD mouse model, are resistant to dietary-induced atherosclerosis since the mice were maintained on an atherosclerosis-resistant genetic background.¹¹ A previous attempt to back-cross Tg2576 mice to C57BL/6 mice, a mouse strain susceptible to dietary-induced atherosclerosis, was unsuccessful due to significant declines in transgene transmission and survival after several generations of back-crossing.¹⁵ We report here the successful transfer of the APP transgene array of Tg2576 mice to the C57BL/6 background and the investigation of the effects of an atherogenic diet on ß-amyloidosis and behavioral functions.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Animals and Diets

Tg2576 mice, on C57BL/6XSJL F2 mixed background and overexpressing human APP with the Swedish double mutation,¹⁶ were back-crossed to C57BL/6J background for 10 to 11 generations to generate a line of APP transgenic mice designated as B6Tg2576 mice. Transgenic mice were identified by polymerase chain reaction (PCR) of tail genomic DNA using human APP-specific primers, 5'CGGAGGAGGATGACTCGGAT3' and 5'CAGCTGCTGTCTCTCGTTGG3'. Production of a DNA fragment of about 500 bp in length by PCR indicated the presence of the human APP transgene. At the age of 7 to 9 months, male and female B6Tg2576 mice and age-matched non-transgenic littermates (n = 21 and 25, respectively) were divided randomly into two groups receiving either an atherogenic diet or a normal diet ad libitum. The atherogenic diet (TD 88051, Teklad, Madison, WI) contains 15.75% fat, 1.25% cholesterol, and 0.5% sodium cholate (w/w) as described by Paigen et al¹⁷ The mice were observed daily for morbidity and mortality and their body weight recorded weekly. After 4 months of diet feeding, these mice were sacrificed for analyses of plasma cholesterol profiles, aortic atherosclerotic lesions, and cerebral ß-amyloidosis. Behavioral functions were assessed in a separate cohort of B6Tg2576 mice (n = 10) and non-transgenic littermates (n = 11) at age of 15 to 18 months after being fed the atherogenic diet for 4 months. All animal procedures used for this study were prospectively reviewed and approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.

Determination of Plasma Total Cholesterol Concentrations and Lipoprotein Cholesterol Profiles

Blood samples were collected from anesthetized animals by retro-orbital bleeding or by cardiac puncture at the end of experiment. Plasma total cholesterol levels were determined colorimetrically by commercial reagents (Infinity cholesterol reagent; Sigma, St. Louis, MO). Plasma lipoprotein cholesterol profiles were analyzed by the chromatographic method developed in our laboratory.¹⁸

Quantification of Aortic Atherosclerosis

Atherosclerotic lesion areas were quantified by the method of Paigen et al¹⁹ with some modifications. Briefly, after mice were anesthetized and exsanguinated, they were perfused through the left ventricle with saline. The hearts were then fixed in 10% neutral buffered formalin for at least 1 week. After the lower two-thirds of the hearts were removed, the remaining tissue was washed thoroughly with distilled water and frozen in freezing medium (OCT Tissue-Tek; Miles Laboratories Ltd, Elkhart, IN), and sectioned in a cryostat at -20°C. Alternate 10-µm sections were saved on slides and observed for the beginning of the aortic root. Sections were then collected for additional 600 µm, or until the aortic cross-section was rounded and the valve cusps were no longer evident. Slides were stained with Oil Red O, and counterstained with hematoxylin. Stained lesion cross-sectional areas were measured in consecutive slides 80 µm apart by image analysis (SigmaScan Pro; SPSS Science, Chicago, IL), and the average lesion area was determined for each aortic sinus over the 400-µm length (five slides) providing the greatest mean lesion area.

Quantification of Cerebral ß-Amyloidosis

Protocols for immunohistochemical analysis developed in our laboratory were used in this study.²⁰ Briefly, formalin-fixed and paraffin-embedded tissue sections were subjected to the avidin-biotin immunoperoxidase method to detect the antigens (eg, Aß) using Vectastain ABC kit (Vector, Burlingame, CA). Primary antibodies used for assessing ß-amyloidosis in the brain of mice included: 6E10 (a monoclonal antibody raised against amino acid 1–16 of Aß, Signet, Dedham, MA), 4G8 (a monoclonal antibody raised against amino acid 17–24 of Aß, Signet), and a polyclonal rabbit anti-Aß antibody (raised against a 30 amino acid synthetic peptide derived from full-length Aß; Zymed, San Francisco, CA). Congo red and thioflavin S were used also to stain amyloid deposits.²¹ The amyloid burden in the cortex and hippocampus of mouse brain were quantified by the histomorphometry system consisting of a Leica DMR research microscope equipped for fluorescence, polarizer/analyzer, and bright-field microscopy, a SPOT RT Slider digital camera (Diagnostic Instruments, Sterling Heights, MI), and the Image Pro Plus v4 image analysis software (Media Cybernetics, Silver Spring, MD) capable of color segmentation and automation via programmable macros. Multiple images of 1 mm² each were captured and analyzed from five coronal brain sections at 500-µm intervals from each mouse using a 10x objective and a 10x eyepiece lens. A total area of 50 mm² giving the highest total Aß immunoreactivity was chosen to calculate the amyloid burden expressed as a percentage of total area covered by Aß immunoreactivity.

Assessment of Behavioral Functions

Three AD-related behavioral functions, spatial learning and memory, exploration of environmental stimuli, and anxiety, were assessed in transgenic and non-transgenic mice after being fed the atherogenic diet or the normal control diet for 4 months. The testing schedule included exploration of the T-maze (days 1 to 10), the open-field (days 1 to 3), the elevated plus-maze (days 4 to 5), and spatial learning in the Morris water maze (days 6 to 11). All equipment and software were purchased from SD Instruments Inc., San Diego, CA.

All testing procedures were described previously.²² Briefly, spontaneous alternation was tested in a T-maze containing a central stem and two side arms. On the initial trial, the mice were placed in the stem with the right arm blocked (forced choice). After entering the available arm, the mice were kept in it for 60 seconds by closing the barrier behind them. The mice were then retrieved and after removing the barrier were immediately placed back in the stem for a free-choice trial. On each of the following 9 days, the same procedure was repeated, except that the blocked arm on the initial trial was changed alternatively from the right to the left. The number of alternations and the latencies before responding were recorded, with a cut-off period of 60 seconds per trial.

Motor activity was measured in an open-field, made of white acrylic with a 50 cm x 50 cm surface area and with each wall reaching 38 cm in height. The activity in the central and peripheral zones was recorded by an overhead video camera and analyzed by video-tracking SMART software (SD Instruments). The mice were placed in the open-field for a 5-minute session daily for 3 days. The distance traveled and the time spent in each zone were measured.

Anxiety was measured in elevated plus-maze, consisting of four arms in a cross-shaped form and a central region. Two of the arms were enclosed on three sides by walls, whereas the other two were not. The enclosed or open arms of the maze faced each other. The mice were placed in the central region and their behavior recorded for 5 minutes per session for 2 days. The number of entries and the time spent in either the enclosed or the open arms were measured.

Spatial orientation was evaluated in the Morris water maze consisting of a round basin (diameter, 112 cm) filled with water (22°C) to a height of 31 cm. The water was made opaque by mixing in dry milk to camouflage the escape platform (8 cm x 8 cm). The pool was placed in a room with abundant extra-maze visual cues. The acquisition of the spatial task consisted of placing the mice next to and facing the wall successively in north (N), east (E), south (S), and west (W) positions, with the escape platform hidden 1 cm beneath water level in the middle of the NE quadrant. In each trial the mouse was allowed to swim until it found the hidden platform, or until 60 seconds had elapsed, at which point the mouse was guided to the platform. The mouse was then allowed to sit on the platform for 10 seconds before being picked up. The escape latency and swim path length (distance) were recorded by the SMART system for four trials daily for 5 days. No pre-training was given before the mice were tested in the Morris water maze.

Statistical Analysis

Data were expressed as mean ± SE. Comparison of treatment groups was performed by two-tailed Student’s t-test, Mann-Whitney rank sum test, and analysis of variance (ANOVA) with repeated measures. Correlations were determined by Pearson product moment correlation analysis. The SigmaStat software (SPSS Science, Chicago, IL) was used for all statistical analyses. P < 0.05 was considered statistically significant.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Age-Dependent Cerebral ß-Amyloidosis in B6Tg2576 Mice

Tg2576 mice overexpress the human APP gene with the Swedish double mutation (KM670/671NL) and develop memory deficits and amyloid plaques in the cortex and hippocampus by 9 to 12 months of age.¹⁶ We back-crossed Tg2576 mice on a C57BL/6XSJL F2 background to C57BL/6 mice for more than 10 generations (B6.Tg2576 [N10 to N11]) and designated them as B6Tg2576 for simplicity. The rate of transgene transmission in B6Tg2576 mice was 36% at weaning (n = 112) and 70% of the transgenic mice survived up to 20 months of age to date.

To determine whether B6Tg2576 mice develop as much age-dependent cerebral ß-amyloidosis as the parental Tg2576 mice, brain sections of B6Tg2576 mice at different ages were subjected to histochemical and immunohistochemical analyses. No Aß immunoreactive deposit was detected before the age of 10 months. After 11 months of age, Aß deposition in the hippocampus and cortex increased significantly with age (Figure 1,a and b) . The ß-amyloid load (percentage of area showing Aß immunoreactivity) was quantified by morphometric analysis. The ß-amyloid load ranged from 0.01% at 11 months to 2% at 18 months of age. These results are comparable to those reported for Tg2576 mice.²³ The Aß deposits appeared mostly as apple-green birefringent amyloid in the neuropil (Figure 1, c and d) and vessel walls (Figure 1, e and f) .

View larger version (137K): [in this window] [in a new window]   Figure 1. Cerebral ß-amyloidosis in B6Tg2576mice. a and b: Brain sections were immunostained with anti-Aß antibody (6E10) and counterstained with hematoxylin as described in Materials and Methods. Aß-immunoreactive deposits are shown in the cortex and hippocampal regions of mice at 13 (a) and 18 (b) months of age on a normal diet. c–f: Congo red-stained brain sections showing an amyloid plaque (arrow) in hippocampus and amyloid deposition in a vessel wall viewed under the regular light (c and e) and the polarized light (d and f) demonstrating apple-green birefringence. g and h: Representative brain sections (immunostained with anti-Aß antibody (6E10) and counterstained with hematoxylin) of B6Tg2576 mice fed a normal diet (g) or an atherogenic diet (h) at 12 months of age, demonstrating about twofold increase of cerebral Aß deposition in atherogenic diet-fed mice. Bars, 200 µm (a and b), 20 µm (c and d), 65 µm (e and f), and 80 µm (g and h).

To test whether an atherogenic diet affects cerebral ß-amyloidosis, B6Tg2576 mice and age matched non-transgenic littermates were fed an atherogenic or a normal control diet for 4 months. Cerebral ß-amyloid load in B6Tg2576 mice (12.3 ± 0.2 months old) fed an atherogenic diet (0.20 ± 0.05%, n = 12) was approximately twofold higher than that of B6Tg2576 mice (12.0 ± 0.3 months old) fed a normal diet (0.09 ± 0.02%, n = 9) (P < 0.05). Representative brain sections from control and atherogenic diet-fed mice are shown in Figure 1, g and h . Age-matched non-transgenic littermates of B6Tg2576 mice had no ß-amyloid deposition in the brain regardless of which diet they were fed (data not shown).

Atherosclerosis in B6Tg2576 Mice

To test if B6Tg2576 mice are susceptible to diet-induced atherosclerosis, samples from B6Tg2576 mice and age matched non-transgenic littermates used for cerebral analyses above were studied for plasma lipoprotein cholesterol profiles and aortic atherosclerosis. The mice fed an atherogenic diet had a significant increase in total plasma cholesterol compared with mice fed a normal diet (168.3 ± 12.0 mg/dl (n = 12) vs. 47.8 ± 4.4 mg/dl (n = 9), P < 0.001). Consistent with previous reports,^11,17 analysis of lipoprotein cholesterol profiles showed that an atherogenic diet increased the concentrations of atherogenic lipoproteins including very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL) and LDL, and decreased the concentration of atheroprotective HDL (Figure 2a) . As expected, the mice fed an atherogenic diet developed significant atherosclerotic lesions (Figure 2, b, c, f, i, and k) . Interestingly, although atherogenic diet-fed B6Tg2576 mice and non-transgenic littermates had similar plasma lipoprotein cholesterol profiles (Figure 2a) , B6Tg2576 mice developed significantly more aortic atherosclerotic lesions than did non-transgenic mice (Figure 2b) . Unexpectedly, B6Tg2576 mice fed a normal diet also developed small but significant early atherosclerotic lesions in the aorta root (Figure 2, d and g) although their lipoprotein cholesterol profiles were normal (Figure 2a) . Non-transgenic littermates, however, showed no atherosclerosis on a normal diet (Figure 2, e and h) . Immunohistochemical analyses showed the co-localization of ß-amyloid immunoreactivity in aortic atherosclerotic lesions from B6Tg2576 mice, but not in lesions from non-transgenic mice (Figure 2, i–n) . These results demonstrated that overexpression of a mutant form of APP initiates and/or accelerates the development of atherosclerosis in a susceptible mouse strain, suggesting a causative role of APP and/or its derivatives in the etiology of atherosclerosis.

View larger version (87K): [in this window] [in a new window]   Figure 2. Plasma lipoprotein cholesterol profiles and aortic atherosclerosis. B6Tg2576 mice and age-matched non-transgenic (non-Tg) littermates were fed an atherogenic diet (A) or a normal control diet (C) for 4 months. a: Representative plasma lipoprotein cholesterol profiles. An atherogenic diet increased levels of atherogenic VLDL and IDL/LDL cholesterol and decreased atheroprotective HDL cholesterol in both B6Tg2576 and non-Tg mice. b: Aortic atherosclerotic lesions in atherogenic diet-fed non-Tg mice (n = 15) and B6Tg2576 mice (n = 12). *, P < 0.05. c–e: Representative frozen sections of hearts, stained by Oil Red O, from an atherogenic diet-fed B6Tg2576 mouse (c), demonstrating atherosclerotic lesions (arrows) in the aortic root region, from a normal diet-fed B6Tg2576 mouse (d), demonstrating small but significant lesions (arrows) in the aortic root, and from a normal diet-fed non-transgenic littermate of B6Tg2576 mice (e). No atherosclerotic lesion was found in normal diet-fed non-transgenic mice (n = 10). f–h: Atherosclerotic lesions in (c-e) at a higher magnification, respectively. i–k: Representative aortic atherosclerotic lesions (stained by Oil Red O) from an atherogenic diet-fed B6Tg2576 mouse (i), a normal diet-fed B6Tg2576 mouse (j), and an atherogenic diet-fed non-transgenic littermate of B6Tg2576 mice (k). l–n: Serial sections of (i–k), respectively, immunostained with anti-Aß antibody (6E10) and counterstained with hematoxylin, demonstrating co-localization of Aß immunoreactivity in atherosclerotic lesions in B6Tg2576 mice (arrows in l and m) but not in non-transgenic mice (n). Bars, 300 µm (c–e) and 150 µm (f–n).

Because no significant difference was observed in cerebral ß-amyloidosis and aortic atherosclerosis regardless of gender (Table 1) , the results from male and female mice were combined. The area of aortic atherosclerotic lesions was positively correlated with amyloid load in the brain of B6Tg2576 mice fed an atherogenic diet (Pearson correlation r = 0.74, P < 0.05, n = 12) (Figure 3a) . Furthermore, a significant positive correlation between aortic atherosclerosis and cerebral ß-amyloidosis was found in B6Tg2576 mice fed a normal diet (Pearson correlation r = 0.79, P < 0.05, n = 9) (Figure 3b) .

View larger version (17K): [in this window] [in a new window]   Figure 3. Correlation of aortic atherosclerosis and cerebral ß-amyloidosis. Quantitative morphometric analyses of aortic atherosclerosis and cerebral ß-amyloidosis were performed as described in Materials and Methods. a: Correlation in atherogenic diet-fed B6Tg2576 mice (n = 12). Pearson correlation r = 0.74, P < 0.05. b: Correlation in normal control diet-fed B6Tg2576 mice (n = 9). Pearson correlation r = 0.79, P < 0.05.

To investigate whether an atherogenic diet affects cognitive functions, a separate cohort of B6Tg2576 mice and non-transgenic littermates fed an atherogenic diet or a normal diet were assessed for their abilities to acquire and process spatial information in the Morris water maze test (submerged platform) by using escape latencies (time needed to find the submerged platform) and path lengths (distances swum) as indicators of learning over 5 days. On a normal diet, B6Tg2576 mice showed learning impairment compared with non-transgenic littermates (Figure 4,a and b) . While non-transgenic mice learned to find the hidden platform with the minimum escape latency by the second day of training, B6Tg2576 mice needed one more day to acquire the same task. When dietary effect was assessed in B6Tg2576 mice, the results showed that the escape latencies (F_1,9 = 18.04, P < 0.01) were much longer in B6Tg2576 mice fed an atherogenic diet than the mice fed a normal diet (Figure 4c) . The concurrent longer path length (F_1,9 = 6.05, P < 0.05) displayed by the atherogenic-diet fed B6Tg2576 mice indicates a spatial learning deficit as opposed to a retarded swimming speed (Figure 4d) . The dietary effect, however, was not significant in non-transgenic mice (escape latency: F_1,8 = 0.28, P = 0.61; path length: F_1,8 = 0.21, P = 0.66) (Figure 4, e and f) , indicating that diet affects learning ability through mutant APP transgene expression.

View larger version (25K): [in this window] [in a new window]   Figure 4. Morris water maze acquisition. B6Tg2576 mice (n = 11) and non-transgenic littermates (n = 10) at age of 15 to 18 months were assessed for their abilities to acquire and process spatial information in the submerged platform version of the Morris water maze after being fed a control normal diet (C) or an atherogenic diet (A) for 4 months. a and b: Spatial learning impairment of B6Tg2576 mice on a normal diet. While non-transgenic mice (non-Tg) learned to find the hidden platform with the minimum escape latency (a) and path length (b) by the second day of training, B6Tg2576 mice needed one more day to acquire the same task. c and d: Diet effect on spatial learning of B6Tg2576 mice. The atherogenic diet was associated with more impaired learning indicated by the increase of escape latencies (c) in the maze acquisition. In agreement with increased escape latencies, the atherogenic diet was associated with a concurrent increase of swimming path length (d) in B6Tg2576 mice, indicating the directional nature of the learning deficit in atherogenic diet-fed mice as opposed to the retarded swimming speed. e and f: Diet effect on escape latencies (e) and path lengths (f) of non-transgenic littermates of B6Tg2576 mice. No significant diet effect was observed in the performance of these non-transgenic mice in the water maze. *, P < 0.05; **, P < 0.01.

Before the Morris water maze test, the same cohort of B6Tg2576 mice was assessed for their willingness to explore the environment in a T-maze, motor activity in an open field, and anxiety in an elevated plus-maze. The results showed no significant differences between atherogenic diet-fed and normal diet-fed B6Tg2576 mice in their performances in these behavioral functions (Table 2) . These data further indicated that increased learning deficit of atherogenic diet-fed B6Tg2576 mice in the Morris water maze was not due to unwillingness to explore or abnormal motor activity and anxiety.

	Discussion

Top Abstract Materials and Methods Results Discussion References

Atherosclerosis is associated with AD or cerebral amyloid angiopathy in humans.^25,26 Aortic atherosclerosis and brain microvasculopathies correlate in patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type.²⁷ The mechanisms by which atherosclerosis and ß-amyloidosis are connected have not been fully understood. The role of cholesterol in atherosclerosis is well established but its role in ß-amyloidosis is not fully understood. Several lines of evidence have suggested that cholesterol may affect ß-amyloidosis by modulation of proteolytic processing of APP and/or subsequent amyloid formation and deposition. The secretion of neuroprotective APPs (the soluble N-terminal derivative of APP following -secretase cleavage) from cultured cells has been shown to decrease following an increase in the cholesterol content of the cells.²⁸ When cellular cholesterol levels are reduced with a cholesterol-lowering drug, the production of Aß is inhibited by an increase in -secretase activity^29,30 and a decrease in both ß- and -secretase activity,^31,32 activities that are involved in the proteolytic processing of APP. In this study, we did not investigated whether atherogenic diet affects cholesterol metabolism in the brain of B6Tg2576 mice. Several studies have provided evidence that plasma cholesterol is transported across the blood-brain barrier. Significant increases in brain cholesterol have been observed in mice fed high cholesterol diets.^10,33 Diet-induced hypercholesterolemia is associated with an increase in amyloidogenic processing of APP and subsequent amyloid deposition in the brain of PSAPP (presenilin1 and APP double transgenic) mice.¹⁰ Furthermore, transport of LDL across the blood-brain barrier has been shown to be mediated by the LDL receptor and has been proposed to be a critical mechanism by which essential lipids, including cholesterol, are delivered to brain cells.³⁴ In addition, cholesterol-lowering agents can decrease levels of cerebral Aß in the brain of guinea pigs and PSAPP mice.^31,35 In summary, these studies support that increased plasma and/or cellular levels of cholesterol may be involved in the etiology of ß-amyloidosis as well as atherosclerosis.

On the other hand, the clearance of Aß may be impaired under the condition of dyslipidemia. In addition to increasing plasma total cholesterol levels, the atherogenic diet used in this study altered the distribution of plasma lipoproteins: atherogenic lipoproteins (VLDL, IDL, and LDL) were increased and the atheroprotective lipoprotein (HDL) was decreased (Figure 2a) . The anti-atherogenic properties of HDL relate partly to its role in reverse cholesterol transport, the removal of cholesterol from peripheral tissues for transport to the liver for excretion.³⁶ In the plasma and brain, Aß is, at least in part, carried on an HDL-like lipoprotein.^37,38 HDL increases the degradation of Aß by microglia in vitro.³⁹ An inverse relationship between plasma HDL levels and the cerebral ß-amyloid load is found in Tg2576 mice fed an atherogenic diet.¹¹ Cultured smooth muscle cells internalize Aß via a receptor-mediated lipoprotein pathway.⁴⁰ Thus, the uptake and degradation of Aß may be lipoprotein-dependent and Aß shares its clearance pathway with cholesterol.

Reports on dietary effects on cognitive functions in humans are not conclusive: vascular risk factors including hypercholesterolemia are associated with cognitive impairment^41,42 while dietary fat and cholesterol intake do not increase the risk for dementia.⁴³ Very recently, in a biracial community study, a high intake of saturated or trans-unsaturated fat has been shown to increase the risk of AD.⁴⁴ In rats, diets high in saturated fat also are associated with cognitive impairment.⁴⁵ Although several studies have reported dietary effects on ß-amyloidosis in transgenic mice,^10-12 behaviors of those mice have not been reported. We demonstrate here that B6Tg2576 mice fed an atherogenic diet are severely impaired in spatial learning as indicated by longer escape latencies during the acquisition of the Morris water maze (Figure 4c) . The concurrent longer path length displayed by the atherogenic-diet fed mice indicates a spatial learning deficit as opposed to a retarded swimming speed (Figure 4d) . In addition, the atherogenic diet-fed B6Tg2576 mice performed similarly to the normal diet-fed B6Tg2576 mice in a T-maze, an open field, and an elevated plus-maze (Table 2) , further indicating that increased learning deficit of atherogenic diet-fed B6Tg2576 mice in the Morris water maze was not due to unwillingness to explore or to abnormal motor activity and anxiety. As all mice tested displayed similar physical activity and swimming ability, no animals were excluded from the analysis. Notably, dietary effect on spatial learning was specifically associated with the mutant APP transgene because the atherogenic diet-fed non-transgenic littermates performed similarly in the Morris water maze to the normal diet-fed mice (Figure 4, e and f) . These results suggest that exacerbation of ß-amyloidosis by an atherogenic diet may be one potential mechanism for its detrimental effect on learning.

While much attention has been focused on the effects of cardiovascular risk factors on the development of AD, little attention has been paid to the role(s) of Aß and/or APP in the etiology of atherosclerosis. In human atherosclerotic plaques, Aß produced from platelet-derived APP may be involved in macrophage activation.⁴⁶ In our study, B6Tg2576 mice fed a normal diet developed small but significant fatty streak aortic lesions that were positively correlated with cerebral ß-amyloid load (Figure 3b) . Moreover, B6Tg2576 mice fed an atherogenic diet developed more atherosclerotic lesions than non-transgenic littermates fed the same diet (Figure 2b) . These differences cannot be fully explained by changes in cholesterol metabolism as plasma lipoprotein cholesterol profiles were similar in B6Tg2576 and non-transgenic mice fed the same diet (Figure 2a) . In B6Tg2576 mice, because the human APP transgene is under the control of a brain-specific prion promoter, Aß/APP immunoreactivity was only detected in the brain (Figure 1) and not in peripheral tissues (data not shown). The plasma Aß level, however, is increased in Tg2576 mice.¹⁶ As Aß can be taken up by vascular smooth muscle cells,⁴⁰ the development of atherosclerotic lesions could be related to the action of Aß on the vessel walls. Indeed, immunohistochemical analysis of the aorta showed that Aß/APP immunoreactivity was co-localized in the atherosclerotic lesions in B6Tg2576 mice (Figure 2, l and m) . Here, we demonstrated that overexpression of a mutant form of APP initiates and/or promotes the development of atherosclerosis in a susceptible mouse strain, suggesting a causative role of APP and/or its derivatives in the etiology of atherosclerosis. These findings warrant further investigations of mechanisms by which ß-amyloidosis and atherosclerosis are connected, in particular, investigation of the roles of Aß and APP in atherogenesis.

In conclusion, by establishing a mouse model that is prone to both atherosclerosis and ß-amyloidosis, we have shown for the first time that aortic atherosclerosis correlates positively with cerebral ß-amyloidosis and that an atherogenic diet is associated with exacerbated learning impairment in APP transgenic mice. Our study supports the concept that anti-atherogenic therapies, including dietary regimens, may be effective in prevention and treatment of AD.

	Acknowledgements

 
We thank Dr. Karen Hsiao Ashe at University of Minnesota for providing Tg2576 mice. We also thank Patti Hall and Terry Lewis for technical assistance, Dr. Robert Lalonde at University of Rouen in France for sharing his expertise in behavioral testing, and Drs. Michael Wyss, G. M. Anantharamiah, and Jere P. Segrest for helpful discussions.

	Footnotes

 
Address reprint requests to Ling Li, D.V.M., Ph.D., Atherosclerosis Research Unit, Department of Medicine, University of Alabama at Birmingham, 1530 3rd Avenue S., BDB 658, Birmingham, AL 35294. E-mail: lili{at}uab.edu

Supported in part by the Alzheimer’s Association (NIRG-00–2281) and the National Institutes of Health (AG16582, AG12850, and NS43947).

Accepted for publication August 5, 2003.

	References

Top Abstract Materials and Methods Results Discussion References

 

1. Sparks DL, Hunsaker JC, III, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR: Cortical senile plaques in coronary artery disease, aging, and Alzheimer’s disease. Neurobiol Aging 1990, 11:601-607[Medline]
2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261:921-923[Abstract/Free Full Text]
3. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A: Serum total cholesterol, apolipoprotein E 4 allele, and Alzheimer’s disease. Neuroepidemiology 1998, 17:14-20[Medline]
4. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE: Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain aß 1–42 levels. Biochem Biophys Res Commun 1998, 252:711-715[Medline]
5. Caramelli P, Nitrini R, Maranhao R, Lourenco AC, Damasceno MC, Vinagre C, Caramelli B: Increased apolipoprotein B serum concentration in Alzheimer’s disease. Acta Neurol Scand 1999, 100:61-63[Medline]
6. Merched A, Xia Y, Visvikis S, Serot JM, Siest G: Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol Aging 2000, 21:27-30[Medline]
7. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443[Abstract/Free Full Text]
8. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000, 356:1627-1631[Medline]
9. Sparks DL, Scheff SW, Hunsaker JC, III, Liu H, Landers T, Gross DR: Induction of Alzheimer-like ß-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994, 126:88-94[Medline]
10. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA: Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000, 7:321-331[Medline]
11. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC: Diet-induced hypercholesterolemia enhances brain Aß accumulation in transgenic mice. Neuroreport 2002, 13:455-459[Medline]
12. Levin-Allerhand JA, Lominska CE, Smith JD: Increased amyloid-levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J Nutr Health Aging 2002, 6:315-319[Medline]
13. Breslow JL: Mouse models of atherosclerosis. Science 1996, 272:685-688[Abstract]
14. Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC: Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer’s disease. Science 1987, 235:873-877[Abstract/Free Full Text]
15. Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK: Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet 1997, 6:1951-1959[Abstract/Free Full Text]
16. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102[Abstract/Free Full Text]
17. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D: Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 1990, 10:316-323[Abstract/Free Full Text]
18. Garber DW, Kulkarni KR, Anantharamaiah GM: A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res 2000, 41:1020-1026[Abstract/Free Full Text]
19. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987, 68:231-240[Medline]
20. Fukuchi K, Pham D, Hart M, Li L, Lindsey JR: Amyloid-ß deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998, 153:1687-1693[Abstract/Free Full Text]
21. Luna L: Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. 1968:pp 153 McGraw-Hill, New York
22. Lalonde R, Dumont M, Fukuchi K, Strazielle C: Transgenic mice expressing the human C99 terminal fragment of ßAPP: effects on spatial learning, exploration, anxiety, and motor coordination. Exp Gerontol 2002, 37:1401-1412[Medline]
23. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T: Age-related amyloid ß deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid ß precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 2000, 157:331-339[Abstract/Free Full Text]
24. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid ß-peptide deposition. Nat Genet 1997, 17:263-264[Medline]
25. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997, 349:151-154[Medline]
26. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A: Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, Part XV. Neurology 1996, 46:1592-1596[Abstract/Free Full Text]
27. Natte R, Vinters HV, Maat-Schieman ML, Bornebroek M, Haan J, Roos RA, van Duinen SG: Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke 1998, 29:1588-1594[Abstract/Free Full Text]
28. Bodovitz S, Klein WL: Cholesterol modulates -secretase cleavage of amyloid precursor protein. J Biol Chem 1996, 271:4436-4440[Abstract/Free Full Text]
29. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of ß-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998, 95:6460-6464[Abstract/Free Full Text]
30. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM: The role of cholesterol in the biosynthesis of ß-amyloid. Neuroreport 1999, 10:1699-1705[Medline]
31. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T: Simvastatin strongly reduces levels of Alzheimer’s disease ß-amyloid peptides Aß 42 and Aß 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98:5856-5861[Abstract/Free Full Text]
32. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the -secretase ADAM 10. Proc Natl Acad Sci USA 2001, 98:5815-5820[Abstract/Free Full Text]
33. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW, Flood DG: Modulation of secreted ß-amyloid precursor protein and amyloid ß-peptide in brain by cholesterol. J Biol Chem 1998, 273:16576-16582[Abstract/Free Full Text]
34. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R: A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997, 138:877-889[Abstract/Free Full Text]
35. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE: A cholesterol-lowering drug reduces ß-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 2001, 8:890-899[Medline]
36. Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadaki KN, Zannis V: Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000, 11:105-115[Medline]
37. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ: Amyloid ß-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996, 271:32916-32922[Abstract/Free Full Text]
38. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J: Biochemical characterization of Alzheimer’s soluble amyloid ß protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 1996, 223:592-597[Medline]
39. Cole GM, Beech W, Frautschy SA, Sigel J, Glasgow C, Ard MD: Lipoprotein effects on Aß accumulation and degradation by microglia in vitro. J Neurosci Res 1999, 57:504-520[Medline]
40. Urmoneit B, Prikulis I, Wihl G, D’Urso D, Frank R, Heeren J, Beisiegel U, Prior R: Cerebrovascular smooth muscle cells internalize Alzheimer amyloid ß protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 1997, 77:157-166[Medline]
41. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001, 56:1683-1689[Abstract/Free Full Text]
42. Stewart R, Richards M, Brayne C, Mann A: Vascular risk and cognitive impairment in an older, British, African-Caribbean population. J Am Geriatr Soc 2001, 49:263-269[Medline]
43. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC, Breteler MM: Diet and risk of dementia: does fat matter?: The Rotterdam Study. Neurology 2002, 59:1915-1921[Abstract/Free Full Text]
44. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Schneider J, Wilson RS: Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003, 60:194-200[Abstract/Free Full Text]
45. Greenwood CE, Winocur G: Cognitive impairment in rats fed high-fat diets: a specific effect of saturated fatty-acid intake. Behav Neurosci 1996, 110:451-459[Medline]
46. De Meyer GR, De Cleen DM, Cooper S, Knaapen MW, Jans DM, Martinet W, Herman AG, Bult H, Kockx MM: Platelet phagocytosis and processing of ß-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res 2002, 90:1197-1204[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Marenchino, P. T. F. Williamson, S. Murri, G. Zandomeneghi, H. Wunderli-Allenspach, B. H. Meier, and S. D. Kramer Dynamics and Cleavability at the {alpha}-Cleavage Site of APP(684-726) in Different Lipid Environments Biophys. J., August 1, 2008; 95(3): 1460 - 1473. [Abstract] [Full Text] [PDF]

				J. Herrmann, S. M. Soares, L. O. Lerman, and A. Lerman Potential Role of the Ubiquitin-Proteasome System in Atherosclerosis: Aspects of a Protein Quality Disease J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2003 - 2010. [Abstract] [Full Text] [PDF]

				D. Cao, H. Lu, T. L. Lewis, and L. Li Intake of Sucrose-sweetened Water Induces Insulin Resistance and Exacerbates Memory Deficits and Amyloidosis in a Transgenic Mouse Model of Alzheimer Disease J. Biol. Chem., December 14, 2007; 282(50): 36275 - 36282. [Abstract] [Full Text] [PDF]

				G. M. Buga, J. S. Frank, G. A. Mottino, M. Hendizadeh, A. Hakhamian, J. H. Tillisch, S. T. Reddy, M. Navab, G. M. Anantharamaiah, L. J. Ignarro, et al. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet J. Lipid Res., October 1, 2006; 47(10): 2148 - 2160. [Abstract] [Full Text] [PDF]

				D. X.-F. Deng, A. Tsalenko, A. Vailaya, A. Ben-Dor, R. Kundu, I. Estay, R. Tabibiazar, R. Kincaid, Z. Yakhini, L. Bruhn, et al. Differences in Vascular Bed Disease Susceptibility Reflect Differences in Gene Expression Response to Atherogenic Stimuli Circ. Res., February 3, 2006; 98(2): 200 - 208. [Abstract] [Full Text] [PDF]

				L. S. Honig, W. Kukull, and R. Mayeux Atherosclerosis and AD: Analysis of data from the US National Alzheimer's Coordinating Center Neurology, February 8, 2005; 64(3): 494 - 500. [Abstract] [Full Text] [PDF]

				J. Krezowski, D. Knudson, C. Ebeling, R. Pitstick, R. K. Giri, D. Schenk, D. Westaway, L. Younkin, S. G. Younkin, K. H. Ashe, et al. Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression Hum. Mol. Genet., September 15, 2004; 13(18): 1989 - 1997. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, L. Articles by Fukuchi, K.-i. Search for Related Content PubMed PubMed Citation Articles by Li, L. Articles by Fukuchi, K.-i.